Quotient Sciences adds UK clinical facility and expands manufacturing site
Quotient Sciences has added pharmacology space at its Nottingham facility and completed a £1.5 million ($1.6 million) expansion of its early development and manufacturing site in Reading.
The UK-headquartered services firm announced the investments this week, framing them as part of its flagship Translational Pharmaceutics platform.
The Nottingham site is a 17,000 square-foot, MHRA-inspected facility that houses 40 beds with volunteer lounges, processing labs, a dispensary and controlled storage. It is located next to Quotient’s formulation development, manufacturing, and clinical operations facility.
Ian Nisbet, global vice president of clinical operations at Quotient Sciences told us “the new clinical pharmacology space at Quotient Sciences Nottingham, the unit will be used to carry-out a wide range of healthy volunteer, Phase I studies.
“The study types typically include First-in-Human, Drug-drug interaction (DDI), Food effect, Bioavailability (BA), Bioequivalence (BE), and Japanese Bridging studies. Within our clinical unit we have two Gamma Cameras enabling us to provide Gamma Scintigraphy studies.”
He added that, “while our clinical unit bed capacity remains unchanged the expansion has allowed us to increase capacity for other activities that enhance and improve the volunteer experience.
“Our new unit is comprised of a dedicated Volunteer Reception area with additional consultation rooms, where outpatient visits are conducted. In addition to this, we have enhanced our volunteer facilities to include a dining area and additional recreational space to ensure our volunteers have the best experience when participating in clinical trials at Quotient Sciences.”
The Reading facility provides a range of early formulation development, analytical and manufacturing services, capacity for which has been doubled. The £1.5 million investment also added office space.
Quotient launched the translational pharmaceutics platform more than 15 years ago. It employs a platform of rapid “make-test” cycles, where drug products are manufactured, released, and dosed in a clinical study in days rather than months.
The system was developed in collaboration with the interaction of both the UK Medicines and Healthcare products Regulatory Agency (MHRA) and the US Food and Drug Administration (FDA).
The investment follows a few months after Quotient expended the translational pharmaceutics system to include drug substance R&D and manufacturing.
At the time the firm cited the acquisition of a facility Alnwick, UK site as the motivation for the expansion, explaining that it provides a more streamlined approach for everything from candidate selection through to commercialization.
DepositPhotos/Rawpixel